{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:12:55Z","timestamp":1790633575890,"version":"4.1.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alemtuzumab (ALZ), a monoclonal antibody used to treat relapsing-remitting multiple sclerosis (RRMS), is associated with a high risk of\u00a0autoimmune thyroid disorders, particularly Graves\u2019 disease (GD). Managing ALZ-induced GD during pregnancy presents unique challenges due to fluctuating thyroid function and potential fetal risks. However, the literature on this specific condition remains limited, with only a few case reports and commentaries available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>The case-history of a 36-year-old woman diagnosed with GD at 11 weeks of gestation, 16 months after receiving her last ALZ dose is described. She was treated with methimazole (MMI), with multiple dose adjustments throughout pregnancy to maintain euthyroidism. Despite persistently elevated TSH receptor antibodies levels, fetal development occurred normally, and she delivered a healthy newborn. The infant experienced transient neonatal hyperthyroidism with spontaneous recovery without treatment. In the postpartum period, both mother and child were closely monitored. As the infant\u2019s condition stabilized, the mother\u2019s MMI dose was gradually increased. At seven months postpartum, she remains euthyroid on 15 mg\/day of MMI, with no clinical\/radiological signs of multiple sclerosis relapse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The present case adds to the limited literature on ALZ-induced GD in pregnancy, providing further insight into the variability of disease onset, progression, and neonatal outcomes. It underscores the importance of close monitoring and a multidisciplinary approach to ensure optimal maternal and fetal health.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1722459","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:48:01Z","timestamp":1768319281000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of alemtuzumab-induced Graves\u2019 disease in pregnancy: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Marsida","family":"Teliti","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Therapeutics, University of Pavia","place":["Pavia, Italy"]},{"name":"Unit of Endocrinology and Metabolism, Laboratory for Endocrine Disruptors, Istituti Clinici Scientifici Maugeri IRCCS","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gallo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Therapeutics, University of Pavia","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Costa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Therapeutics, University of Pavia","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon","family":"Chytiris","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology and Metabolism, Laboratory for Endocrine Disruptors, Istituti Clinici Scientifici Maugeri IRCCS","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Magri","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Therapeutics, University of Pavia","place":["Pavia, Italy"]},{"name":"Unit of Endocrinology and Metabolism, Laboratory for Endocrine Disruptors, Istituti Clinici Scientifici Maugeri IRCCS","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Rotondi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Therapeutics, University of Pavia","place":["Pavia, Italy"]},{"name":"Unit of Endocrinology and Metabolism, Laboratory for Endocrine Disruptors, Istituti Clinici Scientifici Maugeri IRCCS","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519851219","article-title":"Emerging safety issues in alemtuzumab-treated MS patients","volume":"25","author":"Killestein","year":"2019","journal-title":"Multiple Sclerosis J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S134398","article-title":"Alemtuzumab: A review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis","volume":"13","author":"Guarnera","year":"2017","journal-title":"Ther Clin Risk Management"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2009.07.003","article-title":"Immune reconstitution syndrome and the thyroid","volume":"23","author":"Weetman","year":"2009","journal-title":"Best Pract Research: Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad540","article-title":"Prevalence, risk factors, and clinical and biochemical characteristics of alemtuzumab-induced graves disease","volume":"109","author":"Ueland","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab","volume":"74","author":"Baker","year":"2017","journal-title":"JAMA Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00254","article-title":"Autoimmune thyroid diseases in patients treated with alemtuzumab for multiple sclerosis: An example of selective anti-TSH-receptor immune response","volume":"8","author":"Rotondi","year":"2017","journal-title":"Front Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2201","article-title":"Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis","volume":"99","author":"Daniels","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00359","article-title":"Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features","volume":"103","author":"Pariani","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab044","article-title":"Management of severe Graves\u2019 hyperthyroidism in pregnancy following immune reconstitution therapy in multiple sclerosis","volume":"5","author":"Hammerstad","year":"2021","journal-title":"J Endocr Soc"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1159\/000500881","article-title":"2019 European thyroid association guidelines on the management of thyroid dysfunction following immune reconstitution therapy","volume":"8","author":"Muller","year":"2019","journal-title":"Eur Thyroid J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0457","article-title":"2017 Guidelines of the american thyroid association for the diagnosis and management of thyroid disease during pregnancy and the postpartum","volume":"27","author":"Alexander","year":"2017","journal-title":"Thyroid"},{"key":"B12","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/09513590.2022.2087216","article-title":"A unique presentation of Graves\u2019 disease in a pregnant woman with severe hypothyroidism","volume":"38","author":"Rotondi","year":"2022","journal-title":"Gynecological Endocrinology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0413","article-title":"Maternal thyrotropin receptor antibody concentration and the risk of fetal and neonatal thyrotoxicosis: A systematic review","volume":"28","author":"Van Dijk","year":"2018","journal-title":"Thyroid"},{"key":"B14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejogrb.2014.03.007","article-title":"Risk factors for neonatal thyroid dysfunction in pregnancies complicated by Graves\u2019 disease","volume":"177","author":"Uenaka","year":"2014","journal-title":"Eur J Obstetrics Gynecology Reprod Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00981-3","article-title":"Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study","volume":"23","author":"Kazakou","year":"2023","journal-title":"Clin Exp Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02435","article-title":"Letter to the editor: \u201calemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features","volume":"104","author":"Garrahy","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02593","article-title":"Response to letter to the editor: \u201cAlemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features","volume":"104","author":"Thakar","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/1756285614563522","article-title":"Alemtuzumab in the treatment of multiple sclerosis: Key clinical trial results and considerations for use","volume":"8","author":"Havrdova","year":"2015","journal-title":"Ther Adv Neurological Disord"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/ph16050770","article-title":"Monoclonal antibodies in pregnancy and breastfeeding in patients with multiple sclerosis: A review and an updated clinical guide","volume":"16","author":"Gklinos","year":"2023","journal-title":"Pharmaceuticals"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2018.04.004","article-title":"Induction or escalation therapy for patients with multiple sclerosis","volume":"174","author":"Le Page","year":"2018","journal-title":"Rev Neurologique"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1722459\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:48:01Z","timestamp":1768319281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1722459\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2025.1722459"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1722459","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"article-number":"1722459"}}